Diagnostic significance of suppressor of cytokine signalling 3 (SOCS3) methylation and its correlation with IDH1 mutation in Chinese glioma patients

Weili Jiao; Xiaojie Xun; Jinhui Liu; Jianhui Yang; Qi Wang; Lin Wang; Chao Chen; Huijuan Wang; Penggao Dai

doi:10.3109/1354750X.2016.1139001

Diagnostic significance of suppressor of cytokine signalling 3 (SOCS3) methylation and its correlation with IDH1 mutation in Chinese glioma patients

Biomarkers. 2016 Dec;21(8):686-691. doi: 10.3109/1354750X.2016.1139001. Epub 2016 Jul 21.

Authors

Weili Jiao¹, Xiaojie Xun¹, Jinhui Liu¹, Jianhui Yang¹, Qi Wang¹, Lin Wang¹, Chao Chen¹, Huijuan Wang¹, Penggao Dai¹

Affiliation

¹ a The National Engineering Research Center for Miniaturized Detection Systems, School of Life Sciences, Northwest University , Xi'an , PR China.

PMID: 27441955
DOI: 10.3109/1354750X.2016.1139001

Abstract

Context: Epigenetic alterations in suppressor of cytokine signalling 3 (SOCS3) have been suggested as a potential biomarker in glioma.

Objective: To investigate whether SOCS3 methylation could act as a biomarker for glioma grading and prognosis.

Materials and methods: Glioma samples were evaluated by pyrosequencing and quantitative reverse transcription-polymerase chain reaction (qRT-PCR).

Results: SOCS3 promoter methylation was more frequent in the WHO III and (anaplastic) oligoastrocytomas group. SOCS3 methylation status was significantly inversely correlated with mRNA expression level. Mutant IDH1 caused marked increase in SOCS3 methylation.

Conclusion: SOCS3 methylation is a potential biomarker for grading and prognosis in human glioma.

Keywords: Biomarker; IDH1 mutation; SOCS3 methylation; glioma; pyrosequencing.